Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

Table 1 Main clinical and hematological characteristics of patients at diagnosis (n =75)

Variable	Median (range)	N (%) (n = 75)
Age, years	66 (32–83)
< 65		34
≥ 65		41
Gender
Male		52 (69)
Female		23 (31)
Hemoglobin level, g/L	91 (57–136)
< 100		50
≥ 100		25
Leukocyte count, × 10⁹/L	2.9 (0.8–108)
< 4		47
> 4 and < 11		14
≥ 11		14
Platelet count, × 10⁹/L	68 (5–536)
< 100		48
≥ 100		27
Neutrophil count, × 10⁹/L	1.23 (0.09–13.55)
< 0.8		27
≥ 0.8		47
No data		1
Blasts in PB, %	0 (0–74)
< 5		55
≥ 5		20
Blasts in BM, %	15 (0–92)
< 20		49
≥ 20		26
Cytogenetic
Normal karyotype		28
Abnormal karyotype		45
Uninformative CC		2
Cytogenetic category (IPSS-R)
Very good		1
Good		30
Intermediate		20
Poor		6
Very poor		16
Uninformative CC		2
IPSS risk group (only MDS patients: 49)
Intermediate-1		6
Intermediate-2		23
High		19
No data		1
IPSS-R risk group (only MDS patients: 49)
Low		1
Intermediate		9
High		16
Very high		21
No data		2
Treatment
AZA	38
Other treatment (ICE plus AZA and/or ASCT)	37

PB peripheral blood, BM bone marrow, Uninformative CC cases with no metaphases, IPSS International Prognostic Score System, IPSS-R Revised IPSS, WHO World Health Organization, AZA azacitidine, ICE idarubicin, cytarabine and etoposide, ASCT allogeneic stem cell transplantation

ISSN: 1868-7083